Evaluation of a novel web-based prior approval application for palivizumab prophylaxis of respiratory syncytial virus in a state medicaid program

Journal of Managed Care Pharmacy

Volumn 19, Issue 2, 2013, Pages 115-124

  Lundeen, Kristin ^a   Pfeiffenberger, Trista ^b   Vann, Julie Jacobson ^c   O'Brien, Timothy ^a   Sampson, Charlene ^d   Wegner, Steven ^a  

^a AccessCare   (United States)

^b Pharmacy Programs   (United States)

^c AMERICAN INSTITUTES FOR RESEARCH   (United States)

^d North Carolina Division of Aviation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PALIVIZUMAB;

ARTICLE; CHILD; COST EFFECTIVENESS ANALYSIS; DRUG APPROVAL; DRUG COST; DRUG USE; FEMALE; HUMAN; INFANT; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MALE; MEDICAID; PATIENT COMPLIANCE; PRESCHOOL CHILD; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY SYNCYTIAL VIRUS INFECTION; RETROSPECTIVE STUDY; UNITED STATES;

EID: 84874962891     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2013.19.2.115     Document Type: Article

References (27)

1. Express Scripts Inc. 2011 drug trend report. April 2012; 74. http://www.express-scripts.com/research/research/dtr/archive/2012/dtrFinal.pdf. Accessed February 18, 2013.
2. Centers for Disease Control and Prevention. Respiratory syncytial virus (RSV): infection and incidence. January 25, 2010. http://www.cdc.gov/rsv/about/infection.html. Accessed February 18, 2013.
3. Centers for Disease Control and Prevention. Respiratory syncytial virus activity-United States, July 2007-December 2008. MMWR Morb Mortal Wkly Rep. 2008;57(50):1355-58. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5750a3.htm. Accessed February 18, 2013.
4. Boyce TG, Mellen BG, Mitchel EF Jr, Wright PF, Griffin MR. Rates of hospitalization for respiratory syncytial virus infection among children in Medicaid. J Pediatr. 2000;137(6):865-70.
5. Shay DK, Holman RC, Newman RD, Liu LL, Stout JW, Anderson LJ. Bronchiolitis-associated hospitalizations among US children, 1980-1996. JAMA. 1999;282(15):1440-46. http://jama.jamanetwork.com/article.aspx?articleid=192009. Accessed February 18, 2013.
6. Leader S, Kohlhase K. Recent trends in severe respiratory syncytial virus (RSV) among US infants, 1997 to 2000. J Pediatr. 2003;143(5 SUPPL):S127-S132.
7. Synagis (palivizumab) for intramuscular injection. MedImmune. April 2011. http://www.medimmune.com/pdf/products/synagis_pi.pdf. Accessed February 18, 2013.
8. Winterstein AG, Hampp C, Saidi A. Effectiveness of palivizumab prophylaxis in infants and children in Florida. Pharmacoepidemiol Drug Saf. 2012;21(1):53-60.
9. Hampp C, Kauf TL, Saidi AS, Winterstein AG. Cost-effectiveness of respiratory syncytial virus prophylaxis in various indications. Arch Pediatr Adolesc Med. 2011;165(6):492-505.
10. Wegner S, Vann JJ, Liu G, et al. Direct cost analyses of palivizumab treatment in a cohort of at-risk children: evidence from the North Carolina Medicaid program. Pediatrics. 2004;114(6):1612-19.
11. Elhassan NO, Sorbero ME, Hall CB, Stevens TP, Dick AW. Costeffectiveness analysis of palivizumab in premature infants without chronic lung disease. Arch Pediatr Adolesc Med. 2006;160(10):1070-76.
12. Fariña D, Rodriguez SP, Bauer G, et al. Respiratory syncytial virus prophylaxis: cost-effective analysis in Argentina. Pediatr Infect Dis J. 2002;21(4):287-91.
13. Yount LE, Mahle WT. Economic analysis of palivizumab in infants with congenital heart disease. Pediatrics. 2004;114(6):1606-11.
14. Kamal-Bahl S, Doshi J, Campbell J. Economic analyses of respiratory syncytial virus immunoprophylaxis in high-risk infants: a systematic review. Arch Pediatr Adolesc Med. 2002;156(10):1034-41.
15. Frogel M, Nerwen C, Cohen A, et al. Prevention of hospitalization due to respiratory syncytial virus: results from the Palivizumab Outcomes Registry. J Perinatol. 2008;28(7):511-17.
16. Joffe S, Ray GT, Escobar GJ, Black SB, Lieu TA. Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants. Pediatrics. 1999;104(3 Pt 1):419-27.
17. Diehl JL, Daw JR, Coley KC, Rayburg R. Medical utilization associated with palivizumab compliance in a commercial and managed Medicaid health plan. J Manag Care Pharm. 2010;16(1):23-31. http://www.amcp.org/data/jmcp/23-31.pdf.
18. No authors listed. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. Pediatrics. 1998;102(3 Pt 1):531-37.
19. Frogel M, Stewart DL, Hoopes M, Fernandes AW, Mahadevia PJ. A systematic review of compliance with palivizumab administration for RSV immunoprophylaxis. J Manag Care Pharm. 2010;16(1):46-58. http://www.amcp.org/data/jmcp/46-58.pdf.
20. Hampp C, Saidi AS, Winterstein AG. Palivizumab utilization and compliance: trends in respiratory syncytial virus prophylaxis in Florida. J Pediatr. 2010;156(6):953-59.
21. Hand IL, Noble L, Geiss D, Shotkin A. Respiratory syncytial virus immunoprophylaxis in an urban population: a comparison of delivery strategies and outcomes. Pediatr Infect Dis J. 2008;27(2):175-76.
22. Paul DA, Leef KH, Chidekel A, et al. Home delivery of palivizumab: outcomes and compliance in regional preterm infants. Del Med J. 2002;74(1):11-15.
23. Pignotti MS, Indolfi G, Donzelli G. Factors impacting compliance with palivizumab prophylaxis. Pediatr Infect Dis J. 2004;23(2):186-87.
24. Committee on Infectious Diseases. From the American Academy of Pediatrics: Policy statements-modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections. Pediatrics. 2009;124(6):169-701.
25. Jacobson Vann J, Feaganes J, Wegner S. Reliability of Medicaid claims versus medical record data: in a cost analysis of palivizumab. Pharmacoeconomics. 2007;25(9):793-800.
26. Welch BL. The generalisation of student's problems when several different population variances are involved. Biometrika. 1947;34(1-2):23-35.
27. URAC Pharmacy Quality Management. The patient-centered outgrowth of specialty pharmacy: why patient management strategies are critical to 21st century providers. URAC Specialty Pharmacy White Paper. 2011. https://www.urac.org/Whitepaper/PQM-Specialty_Pharmacy.pdf. Accessed February 18, 2013.